Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Scheipner, L; Zurl, H; Altziebler, JV; Pichler, GP; Schöpfer-Schwab, S; Jasarevic, S; Gaisl, M; Pohl, KC; Pemberger, K; Andlar, S; Hutterer, GC; Bele, U; Leitsmann, C; Leitsmann, M; Augustin, H; Zigeuner, R; Ahyai, S; Mischinger, J.
Charlson-Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2023; 15(24):
Doi: 10.3390/cancers15245770
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Scheipner Lukas
- Co-Autor*innen der Med Uni Graz
- Ahyai Sascha
- Altziebler Julia Valerie
- Augustin Herbert
- Bele Uros
- Gaisl Michael
- Hutterer Georg
- Jasarevic Samra
- Leitsmann Conrad
- Leitsmann Marianne
- Mischinger Johannes
- Pemberger Karl
- Pichler Georg
- Schöpfer-Schwab Stephanie
- Zigeuner Richard
- Zurl Hanna
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: To test the association between the Charlson-Deyo Comorbidity Index (CCI) and the recurrence of non-muscle-invasive bladder cancer (NMIBC). METHODS: NMIBC (Ta, T1, TIS) patients who underwent transurethral resection of bladder tumor (TURB) between 2010 and 2018 were identified within a retrospective data repository of a large university hospital. Kaplan-Meier estimates and uni- and multivariable Cox regression models tested for differences in risk of recurrence according to low vs. high comorbidity burden (CCI ≤ 4 vs. >4) and continuously coded CCI. RESULTS: A total of 1072 NMIBC patients were identified. The median follow-up time of the study population was 55 months (IQR 29.6-79.0). Of all 1072 NMIBC patients, 423 (39%) harbored a low comorbidity burden vs. 649 (61%) with a high comorbidity burden. Overall, the rate of recurrence was 10% at the 12-month follow-up vs. 22% at the 72-month follow-up. In low vs. high comorbidity burden groups, rates of recurrence were 6 vs. 12% at 12 months and 18 vs. 25% at 72 months of follow-up (p = 0.02). After multivariable adjustment, a high comorbidity burden (CCI > 4) independently predicted a higher risk of recurrence (HR 1.42, 95% confidence interval (CI) 1.06-1.92, p = 0.018). After multivariable adjustment, the hazard of recurrence increased by 5% per each one-unit increase on the CCI scale (HR 1.05, 95% CI 1.00-1.10, p = 0.04). CONCLUSIONS: Comorbidities in NMIBC patients are common. Our data suggest that patients with higher CCI have an increased risk of BC recurrence. As a consequence, patients with a high comorbidity burden should be particularly encouraged to adhere to NMIBC guidelines and conform to follow-up protocols.
- Find related publications in this database (Keywords)
- CCI
- NMIBC
- recurrence
- Charlson comorbidity index
- predictor